AACP
NEO icon

Advantage Alpha Capital Partners’s NeoGenomics NEO Stock Holding History

Advantage Alpha Capital Partners’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-169,919
Closed -$2.06M – 121
2022
Q1 		$2.06M Buy
169,919
+115,972
+215% +$2.44M 0.31% 89
2021
Q4 		$1.84M Buy
+53,947
New +$2.11M 0.26% 90

Other funds holding NEO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Advantage Alpha Capital Partners's NEO Position: Q2 2022 in Review

Advantage Alpha Capital Partners sold out of NeoGenomics (NEO) in Q2 2022, closing a stake of 169,919 shares — an estimated $2.06M sold.

Advantage Alpha Capital Partners first reported a position in NEO in Q4 2021 and held it in 2 quarters. The position peaked at $2.06M in Q1 2022. 239 funds tracked by Wall St. Rank hold NEO as of Q2 2022.

  • Advantage Alpha Capital Partners reported no remaining NeoGenomics position as of Q2 2022 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 169,919 NeoGenomics shares in Q2 2022, an estimated $2.06M.
  • Advantage Alpha Capital Partners first reported a position in NeoGenomics in Q4 2021 and held it in 2 quarters.
  • Advantage Alpha Capital Partners's NeoGenomics position peaked at $2.06M in Q1 2022.
  • 239 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2022.

Based on Advantage Alpha Capital Partners's 13F filing for Q2 2022, filed 12 Aug 2022.